Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Lee Jackson | Oct 20, 2014 at 8:35 AM EDT

Merrill Lynch’s 5 Destroyed Biotech Stocks With 100% or More Upside Potential

A new report from Merrill Lynch highlights five biotechs that have been absolutely crushed but have outstanding potential and catalysts…

Chris Lange | Oct 17, 2014 at 1:40 PM EDT

Ebola Stocks Move in Different Directions

Recently we have seen a surge in Ebola-related stocks across the board, but Friday trading brought a mixed view for…

Chris Lange | Oct 16, 2014 at 2:05 PM EDT

Ebola Stocks on the Move

Investors fan the flames of Ebola fears in the market, enabling these biotech companies to profit from these fears.

Lee Jackson | Oct 16, 2014 at 8:35 AM EDT

Analyst Top Biotech Stocks Could Explode After Huge Sell-Off

In a new report, Stifel analysts highlight their top biotech stocks with strong earnings momentum and possible catalysts to buy…

Paul Ausick | Oct 14, 2014 at 9:05 AM EDT

Drug Sales Energize Johnson & Johnson Earnings

Johnson & Johnson reported better-than-expected third-quarter 2014 results before markets opened Tuesday.

Chris Lange | Oct 13, 2014 at 10:00 AM EDT

Ebola Fears Driving Ebola Stock Winners

Fears of Ebola have plagued the United States since late September, and some biotech companies have capitalized on this fear.

Lee Jackson | Oct 13, 2014 at 8:40 AM EDT

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech…

Paul Ausick | Oct 10, 2014 at 11:45 AM EDT

Diplomat Turns Bunt Pricing Into Homerun for IPO Buyers

Diplomat Pharmacy priced its IPO shares at $13 on Thursday, but when the stock began trading Friday morning it opened…

Chris Lange | Oct 10, 2014 at 10:10 AM EDT

Short Interest in Biotech Becomes Company Specific

The short interest data are out for the end of September settlement date, and 24/7 Wall St. has reviewed the…

Chris Lange | Oct 9, 2014 at 2:05 PM EDT

How Much More Can Lakeland Rise?

Lakeland Industries shares have skyrocketed since the beginning of October as investors take a pessimistic view on recent Ebola news.

Douglas A. McIntyre | Oct 9, 2014 at 6:29 AM EDT

Ebola Outbreak Could Cost $32 Billion — World Bank

The World Bank has put out an estimate of what a wider outbreak of Ebola could cost: $32 billion.

Chris Lange | Oct 8, 2014 at 3:48 PM EDT

Unilife Finds Second Wave

ThinkstockUnilife Corporation (NASDAQ: UNIS) is riding the wave Wednesday as it watches its shares surf into the close. While this…

Chris Lange | Oct 8, 2014 at 12:30 PM EDT

Histogenics Files for IPO

Histogenics Corp. has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.

Jon C. Ogg | Oct 8, 2014 at 12:20 PM EDT

Ebola Drug Stocks React Wildly to Dallas Patient Death

The sad news that Ebola patient Thomas Eric Duncan has died in a Dallas hospital now raises fears that Ebola…

Jon C. Ogg | Oct 8, 2014 at 11:15 AM EDT

How Ebola Could Cost the World $32 Billion by End of 2015

The World Bank projects what the potential costs could be if the Ebola epidemic were to significantly infect people in…

1 … 278 279 280 281 282 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Merrill Lynch’s 5 Destroyed Biotech Stocks With 100% or More Upside Potential

Ebola Stocks Move in Different Directions

Ebola Stocks on the Move

Analyst Top Biotech Stocks Could Explode After Huge Sell-Off

Drug Sales Energize Johnson & Johnson Earnings

Ebola Fears Driving Ebola Stock Winners

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Diplomat Turns Bunt Pricing Into Homerun for IPO Buyers

Short Interest in Biotech Becomes Company Specific

How Much More Can Lakeland Rise?

Ebola Outbreak Could Cost $32 Billion — World Bank

Unilife Finds Second Wave

Histogenics Files for IPO

Ebola Drug Stocks React Wildly to Dallas Patient Death

How Ebola Could Cost the World $32 Billion by End of 2015

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Morgan Stanley Lifts IonQ Price Target to $47: Is the Quantum Computing Stock Finally Ready to Deliver?

Market Greed Is Back: Oil and the Hormuz Strait Didn’t Get the Memo.

Big Oil Has Transformed Into Shareholder-Friendly Cash Machines, Says CNBC’s Halftime Report

Social Security Cuts Inch Closer to Reality as Lawmakers Weigh Options

A $2 Million Portfolio Still Has a Safety Trap Most Investors Over 60 Miss

Oppenheimer Upgrades Airbnb to Outperform With $180 Price Target: Are Hotels and the World Cup About to Re-Rate the Stock?

AMD Will Be a $1 Trillion Company Faster Than You Think

Health and Healthcare Articles

All Health and Healthcare Articles

Merrill Lynch’s 5 Destroyed Biotech Stocks With 100% or More Upside Potential

Ebola Stocks Move in Different Directions

Ebola Stocks on the Move

Analyst Top Biotech Stocks Could Explode After Huge Sell-Off

Drug Sales Energize Johnson & Johnson Earnings

Ebola Fears Driving Ebola Stock Winners

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Diplomat Turns Bunt Pricing Into Homerun for IPO Buyers

Short Interest in Biotech Becomes Company Specific

How Much More Can Lakeland Rise?

Ebola Outbreak Could Cost $32 Billion — World Bank

Unilife Finds Second Wave

Histogenics Files for IPO

Ebola Drug Stocks React Wildly to Dallas Patient Death

How Ebola Could Cost the World $32 Billion by End of 2015

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Morgan Stanley Lifts IonQ Price Target to $47: Is the Quantum Computing Stock Finally Ready to Deliver?

Market Greed Is Back: Oil and the Hormuz Strait Didn’t Get the Memo.

Big Oil Has Transformed Into Shareholder-Friendly Cash Machines, Says CNBC’s Halftime Report

Featured Reads

Social Security Cuts Inch Closer to Reality as Lawmakers Weigh Options

A $2 Million Portfolio Still Has a Safety Trap Most Investors Over 60 Miss